Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
NCT00382629Phase 2Completed
- Sponsor
- Bayhill Therapeutics, Inc.
- Start
- Feb 2006
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 2, randomised, double-blind trial of bht-3009 in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Bayhill Therapeutics, Inc. Primary endpoint: Mean 4-week rate of occurrence of new gadolinium (Gd) enhancing MRI lesions at 48 weeks. Started Feb 2006; status: completed.
02
Drugs
bht-3009
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00382629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382629.